Clinical Significance of von Willebrand Factor-Cleaving Protease (ADAMTS13) Deficiency in Patients with Sepsis-Induced Disseminated Intravascular Coagulation

다국어 초록 (Multilingual Abstract)

Background : Deficiency of von Willebrand factor-cleaving protease, a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), is thought to be responsible for platelet aggregation and microthrombi formation, which in turn cause typical thrombotic microangiopathies. This deficiency is found in patients with thrombocytopenia-associated multiple organ failure such as thrombocytopenic purpura and disseminated intravascular coagulation (DIC). We evaluated the clinical significance of ADAMTS13 deficiency in patients with sepsis-induced DIC.
Materials and Methods : Nineteen patients with sepsis-induced DIC were enrolled. ADAMTS13 antigen levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and activity levels were measured by fluorescence resonance energy transfer assay. Patients were categorized into two groups according to ADAMTS13 antigen level: less than 350 ng/mL or above. Clinical characteristics and survival were compared between the two groups.
Results : ADAMTS13 antigen level was less than 350 ng/mL in 7 patients and was above 350 ng/mL in 12 patients. There were no significant differences between the groups for age, sex, severity of illness, and other clinical characteristics. In patients with ADAMTS13 antigen level less than 350 ng/mL, in-hospital mortality was much higher (100% versus 25%, P=0.003) and 7-day survival was much shorter (P=0.023).
Conclusion : Deficiency of ADAMTS13 could be thought to be associated with unfavorable outcome in patients with sepsis-induced DIC.

다국어 초록 (Multilingual Abstract)

Background : Deficiency of von Willebrand factor-cleaving protease, a disintegrin-like and metalloprotease with thrombospondin type 1 motif 13 (ADAMTS13), is thought to be responsible for platelet aggregation and microthrombi formation, which in turn cause typical thrombotic microangiopathies. This deficiency is found in patients with thrombocytopenia-associated multiple organ failure such as thrombocytopenic purpura and disseminated intravascular coagulation (DIC). We evaluated the clinical significance of ADAMTS13 deficiency in patients with sepsis-induced DIC.
Materials and Methods : Nineteen patients with sepsis-induced DIC were enrolled. ADAMTS13 antigen levels were determined by Enzyme-Linked Immunosorbent Assay (ELISA) and activity levels were measured by fluorescence resonance energy transfer assay. Patients were categorized into two groups according to ADAMTS13 antigen level: less than 350 ng/mL or above. Clinical characteristics and survival were compared between the two groups.
Results : ADAMTS13 antigen level was less than 350 ng/mL in 7 patients and was above 350 ng/mL in 12 patients. There were no significant differences between the groups for age, sex, severity of illness, and other clinical characteristics. In patients with ADAMTS13 antigen level less than 350 ng/mL, in-hospital mortality was much higher (100% versus 25%, P=0.003) and 7-day survival was much shorter (P=0.023).
Conclusion : Deficiency of ADAMTS13 could be thought to be associated with unfavorable outcome in patients with sepsis-induced DIC.

참고문헌 (Reference)

1 Bianchi V, "Von Willebrand factor-cleaving protease (ADAMTS13) in thrombocytopenic disorders: a severely deficient activity is specific for thrombotic thrombocytopenic purpura" 100 : 710-713, 2002

2 Mannucci PM, "Von Willebrand factor cleaving protease (ADAMTS- 13) in 123 patients with connective tissue diseases (systemic lupus erythematosus and systemic sclerosis)" 88 : 914-918, 2003

3 Gando S, "Tissue factor production not balanced by tissue factor pathway inhibitor in sepsis promotes poor prognosis" 30 : 1729-1734, 2002

4 Moake JL, "Thrombotic microangiopathies" 347 : 589-600, 2002

5 Green J, "The tissue factor and plasminogen activator inhibitor type-1 response in pediatric sepsis-induced multiple organ failure" 87 : 218-223, 2002

6 American College of Chest Physicians, "Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis" 20 : 864-874, 1992

7 Ono T, "Severe secondary deficiency of von Willebrand factor-cleaving protease (ADAMTS13) in patients with sepsis-induced disseminated intravascular coagulation: its correlation with development of renal failure" 107 : 528-534, 2006

8 Nguyen TC, "Plasma therapies in thrombotic syndromes" 28 : 459-465, 2005

9 Furlan M, "Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis" 87 : 4223-4234, 1996

10 Loof AH, "Low activity of von Willebrand factor-cleaving protease is not restricted to patients suffering from thrombotic thrombocytopenic purpura" 112 : 1087-1088, 2001

11 Kokame K, "FRETS-VWF73, a first fluorogenic substrate for ADAMTS13 assay" 129 : 93-100, 2005

12 Moore JC, "Decreased von Willebrand factor protease activity associated with thrombocytopenic disorders" 98 : 1842-1846, 2001

13 Mannucci PM, "Changes in health and disease of the metalloprotease that cleaves von Willebrand factor" 98 : 2730-2735, 2001

14 Nguyen TC, "Bench-to-bedside review: thrombocytopenia-associated multiple organ failure-a newly appreciated syndrome in the critically ill" 10 : 235-, 2006

15 Furlan M, "Acquired deficiency of von Willebrand factor-cleaving protease in a patient with thrombotic thrombocytopenic purpura" 91 : 2839-2846, 1998

16 Nguyen TC, "Acquired ADAMTS-13 deficiency in pediatric patients with severe sepsis" 92 : 121-124, 2007

17 Knaus WA, "APACHE II: a severity of disease classification system" 13 : 818-829, 1985